BPC-157 (Body Protection Compound 157) is among the most extensively studied synthetic research peptides. A 15-amino acid sequence derived from human gastric juice protein, it has generated substantial evidence across gastrointestinal biology, musculoskeletal repair, vascular biology, and neuroscience. Few research peptides demonstrate activity across such a wide range of tissue systems with this degree of mechanistic coherence.

BPC-157 is sold strictly for in-vitro laboratory and research use only.

What Is BPC-157?

BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a pentadecapeptide first characterized by Professor Predrag Sikiric at the University of Zagreb. A partial sequence of body protection compound found in human gastric juice, it demonstrates exceptional stability in gastric acid -- making it useful for oral administration studies in GI research models.

Core Mechanisms of Action

Nitric Oxide System Modulation

BPC-157 activates endothelial nitric oxide synthase (eNOS), enhances NO bioavailability in vascular endothelium, and modulates blood flow and mucosal perfusion. NOS inhibitors attenuate but do not fully eliminate protective effects in ulcer models -- indicating both NO-dependent and NO-independent pathways (Sikiric et al., 2013).

Angiogenesis via VEGF Upregulation

BPC-157 consistently upregulates VEGF in healing tissue. Enhanced angiogenesis delivers oxygen and growth factors to regenerating tissue -- underpinning effects in both GI mucosal repair and musculoskeletal healing.

FAK-Paxillin Pathway in Connective Tissue

In tendon fibroblast cultures, BPC-157 activates focal adhesion kinase (FAK) and paxillin -- central to cell adhesion, migration, and ECM remodeling. This promotes the coordinated fibroblast behavior required for tendon and ligament regeneration.

Gastrointestinal Research: The Deepest Evidence Base

Over 50 preclinical publications examine BPC-157 effects in gastric ulcer, colitis, intestinal anastomosis, and esophageal injury models. Studies using ethanol, indomethacin, acetic acid, and cysteamine-induced ulcers consistently show BPC-157 accelerates healing, reduces lesion area, and restores mucosal architecture.

Inflammatory Bowel Research

In DSS and TNBS colitis models, BPC-157 reduces TNF-alpha, IL-6, and IL-1beta, restores colon crypt architecture, and lowers intestinal permeability markers (Chang et al., 2021). For complementary gut inflammation research, KPV -- an alpha-MSH tripeptide -- is sometimes studied alongside BPC-157 to probe different anti-inflammatory pathways.

Musculoskeletal and Tendon Research

Achilles tendon transection is the most replicated musculoskeletal model for BPC-157. Studies consistently show faster functional recovery, improved tendon biomechanics, enhanced collagen fiber organization, and upregulation of tendon-specific marker genes. Ligament, muscle crush, and fracture models show comparable accelerated healing patterns.

Neurological Research

  • Peripheral nerve injury -- Crush injury models report enhanced functional recovery and elevated NGF levels.
  • Spinal cord research -- Compression injury studies show reduced inflammatory infiltration and preserved motor function.
  • Dopamine system -- BPC-157 has been investigated for dopaminergic signaling modulation relevant to L-DOPA and addiction research.
  • Blood-brain barrier -- Research suggests preservation of BBB integrity following TBI.

Combination Research: BPC-157 with TB-500 and GHK-Cu

BPC-157 and TB-500 (Thymosin Beta-4) are the most commonly co-studied healing peptides. BPC-157 works through NO/VEGF/FAK pathways; TB-500 operates through actin sequestration and AcSDKP-mediated anti-fibrosis -- complementary mechanisms addressing different repair phases. Pre-formulated BPC-157 + TB-500 + GHK-Cu blends are available at PeptideBull for multi-pathway healing research.

Preparation Notes

BPC-157 is supplied as lyophilized powder. Reconstitute with bacteriostatic water; store reconstituted solutions at 4 degrees C for up to 28 days. Research-grade BPC-157 from PeptideBull is HPLC-tested to 99%+ purity with COA documentation available.

Disclaimer: All products are for in-vitro research use only. Not for human consumption or therapeutic application.